Nachrichten zur NanoViricides Aktie

Market movers: Alphabet, Millennial Potash, NanoViricides...

…

NanoViricides raises cash, moves broad-spectrum antiviral NV-387 into Phase II trials

NanoViricides (NYSE-A:NNVC) is advancing its broad-spectrum antiviral NV-387, backed by new financing that strengthens its balance sheet and supports...…

Small cap wrap: American Resources, NanoViricides, AtaiBeckley…

…

NanoViricides raises $6M in direct offering with institutional investor

NanoViricides (NYSE-A:NNVC) said on Tuesday it has entered into a securities purchase agreement with a single healthcare institutional investor to raise...…

Small cap wrap: Millennial Potash, EnWave, NanoViricides, HIVE Digital Technologies…

…

NanoViricides receives approval to start Phase II clinical trial of NV-387 for MPox treatment in DRC

NanoViricides (NYSE-A:NNVC) announced that it has received approval to begin its Phase II Clinical Trial of NV-387 for the Treatment of MPox by the...…

Tesla, Take-Two Interactive, Airbnb, Alvopetro, NanoViricides: What brokers said this week

…

NanoViricides’ NV-387 shows broad antiviral potential, says Zacks

Analysts at Zacks have issued a new report on clinical stage biotech NanoViricides (NYSE-A:NNVC), saying that its lead drug candiate…

NanoViricides targets broad-spectrum virus threats

NanoViricides (NYSE-A:NNVC) CEO Dr Anil Diwan talked with Proactive about the company’s latest progress with its broad-spectrum antiviral candidate, NV-387....…

NanoViricides’ NV-387 shows potent anti-measles activity, highlighting broad-spectrum potential

…

Small cap wrap: Nevis Brands, Sonoro Gold, NanoViricides, Medicus Pharma…

…

NanoViricides reports antiviral activity of NV-387 against measles in preclinical studies

NanoViricides (NYSE-A:NNVC) said on Wednesday its experimental drug NV-387 showed strong activity against the measles virus in both cell culture…

Small cap wrap: NanoViricides, Century Lithium, Standard Uranium, Charbone Hydrogen…

…

NanoViricides says antiviral candidate NV-387 could address global measles surge

NanoViricides (NYSE-A:NNVC) said on Wednesday that its antiviral candidate NV-387 could play a key role in addressing the growing number of…

NanoViricides eyes revenue opportunities with broad-spectrum antiviral NV-387

NanoViricides (NYSE-A:NNVC) said on Wednesday that its broad-spectrum antiviral candidate NV-387 has shown strong preclinical efficacy against multiple...…

NanoViricides says lead antiviral boosted survival in measles-infected mice

NanoViricides (NYSE-A:NNVC) said on Monday that its broad-spectrum antiviral candidate, NV-387, showed strong effectiveness in preclinical studies using a...…

NanoViricides says MPox drug candidate NV-387 poised for Phase II trial as WHO extends global health emergency

NanoViricides (NYSE-A:NNVC) is preparing for Phase II clinical testing in Africa, following the World Health Organization’s recent extension of the…

NanoViricides positioned at forefront of Mpox treatment efforts, says Zacks

NanoViricides (NYSE-A:NNVC) is preparing to launch a Phase 2 clinical trial of its lead antiviral candidate NV-387 for the treatment…

Market movers: Autodesk, Waters, NanoViricides...

…

NanoViricides nears completion of clinical trial design for MPox treatment

NanoViricides (NYSE-A:NNVC) said on Monday it is close to finalizing the design of a Phase II adaptive clinical trial for…

NanoViricides advances antiviral candidate NV-387 into Phase 2 trials for Mpox

NanoViricides (NYSE-A:NNVC) announced it is moving forward with Phase 2 clinical development of its experimental antiviral therapy, NV-387, for the...…

Small cap wrap: Fineqia, NanoViricides, Standard Uranium...

…

NanoViricides touts antiviral NV-387 as tool against new COVID variant

NanoViricides (NYSE-A:NNVC) said its experimental antiviral drug NV-387 could play a role in combating emerging threats from COVID-19 and bird…

NanoViricides commissions animal study of broad-spectrum antiviral for measles

NanoViricides (NYSE-A:NNVC) said it is advancing its measles drug development program with a new animal trial to evaluate its antiviral…

NanoViricides president backs FDAs targeted COVID booster policy shift

NanoViricides (NYSE-A:NNVC) president Dr Anil Diwan has welcomed a new US Food and Drug Administration policy that limits broad COVID-19…

NanoViricides advances NV-387 antiviral program, eyes Phase II trials for Mpox

NanoViricides (NYSE-A:NNVC) is preparing a Phase II clinical trial application for its lead antiviral candidate NV-387 to treat Mpox infections…

NanoViricides progresses antiviral portfolio as measles and MPox threats rise

NanoViricides Inc (NYSE American: NNVC) said on Wednesday it is moving forward with trials of its antiviral drug NV-387 to…

NanoViricides wins ethics approval for Phase II Mpox drug trial in DRC

NanoViricides (NYSE-A:NNVC) said on Thursday it has received ethics committee approval in the Democratic Republic of Congo to move forward…

NanoViricides advances measles drug development amid rising US cases

NanoViricides (NYSE-A:NNVC) said it is moving forward with the development of a drug to treat measles, as US health officials…

NanoViricides evaluating antiviral drug NV-387 for measles treatment

NanoViricides (NYSE-A:NNVC) has begun evaluating its clinical-stage antiviral NV-387 for the treatment of measles, a disease with no currently approved…

NanoViricides unaffected by US tariff turmoil, says CFO

NanoViricides (NYSE-A:NNVC) chief financial officer Meeta Vyas talked with Proactive about the company’s progress developing broad-spectrum antiviral...…

NanoViricides unimpacted by tariffs; sees boost by changes at government agencies

…

NanoViricides highlights broad-spectrum antiviral strategy and progress with lead drug candidate

…

NanoViricides eyes role in US bird flu fight as USDA unveils $100M initiative

The US Department of Agriculture (USDA) will invest up to $100 million to combat highly pathogenic avian influenza (HPAI), funding…

NanoViricides says business unaffected by US tariffs, highlights antiviral pipeline

NanoViricides (NYSE-A:NNVC) said on Tuesday that its business remains unaffected by US government tariffs, retaliatory trade policies, or federal spending...…

Mpox – a possible US$100mln+ opportunity

Nanoviricides (NV), a US company, targets the unmet medical need for an effective, broad-spectrum acute antiviral therapy with NV-387. NV…

NanoViricides targets key milestones in 2025 with NV-387 advancing to Phase II trials

NanoViricides (NYSE-A:NNVC) is positioning itself for a pivotal year in 2025, with plans to advance its lead antiviral candidate, NV-387,…

NanoViricides announces readiness to combat bird flu with antiviral drug NV-387

NanoViricides (NYSE-A:NNVC) stated today that it is prepared to address the escalating threat of bird flu with its broad-spectrum antiviral…

NanoViricides seeks to eliminate treatment delays with its broad spectrum antiviral NV-387

With its broad-spectrum antiviral drug NV-387, NanoViricides (NYSE-A:NNVC) sees a future where patients with a range of viral diseases can access…

NanoViricides warns of bird flu pandemic as outbreak spreads in Massachusetts

Bird flu is likely widespread among birds in Massachusetts, State health and environmental officials said this week on Wednesday, as…

NanoViricides advances antiviral drug with Phase II Clinical trial to Combat MPox

…

NanoViricides taps clinical research organization for Phase II trial of NV-387

NanoViricides (NYSE-A:NNVC) said on Monday it had engaged a clinical research organization to conduct a Phase II trial for its…

NanoViricides CEO discusses NV-387’s broad spectrum promise

NanoViricides (NYSE-A:NNVC) CEO Dr Anil Diwan joined Proactive to highlight the company’s lead drug candidate NV-387, which is targeting multiple…

NanoViricides highlights urgent need for broad-spectrum antiviral solutions amid viral threats

NanoViricides (NYSE-A:NNVC) has highlighted the growing need for innovative antiviral solutions amid rising concerns over multiple viral threats, including...…

NanoViricides CEO discusses groundbreaking broad-spectrum antiviral treatment

…

NanoViricides sees NV-387 as a key defense against bird flu pandemic

NanoViricides (NYSE-A:NNVC) said it believes that its broad-spectrum antiviral candidate, NV-387, could be a critical tool in combating a potential…

NanoViricides CEO highlights urgency of H5N1 preparedness as cases rise in North America

The rise of unexplained human cases of bird flu in North America means there is an urgent need for effective…

NanoViricides pushes NV-387 to Phase II trials

NanoViricides (NYSE-A:NNVC) reported progress on its lead antiviral drug NV-387 and revealed plans to advance Phase II clinical trials for…

NanoViricides prepares for Phase II trials for antiviral NV-387

NanoViricides (NYSE-A:NNVC) filed its annual report, announcing that its broad-spectrum antiviral NV-387 is progressing to Phase II clinical trials, with...…

NanoViricides expands antiviral drug pipeline with TheraCour Pharma agreement

NanoViricides (NYSE-A:NNVC) announced that it has signed a Memorandum of Understanding (MOU) with TheraCour Pharma, granting it the right of…